Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (4573)	6/27/1998 7:25:00 PM
From: Peter Singleton	of 6136

Rick, excellent article on angiogenesis ... noticed the author had the same name as yours! would be a good addition to a website called "Links to Agouron" if you're ever inclined to put one together ... : ) I attended a presentation by David Corresh (sp?) of the Salk Institute a few weeks ago. Dr. Corresh is apparently a leading researcher in this area. He made the same point about the endothelial growth factors you did ... there's a bunch of them that induce angiogenesis, which might limit the effectiveness of a drug that targeted just one of them. They're working with integrins, and are extremely positive about their potential. They are developing a mAB with Ixysys which is early in the clinic, and working on small molecule inhibitors with Merck KGaA in Germany. Corresh is also optimistic re: MMP2 inhibitors. I haven't confirmed, but I imagine MMP2 is one of the MMP enzymes AG3340 is targeted at. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next